Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 3
2008 1
2009 1
2012 1
2013 2
2016 2
2017 2
2019 3
2020 7
2021 2
2022 4
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839.
Bothe U, Günther J, Nubbemeyer R, Siebeneicher H, Ring S, Bömer U, Peters M, Rausch A, Denner K, Himmel H, Sutter A, Terebesi I, Lange M, Wengner AM, Guimond N, Thaler T, Platzek J, Eberspächer U, Schäfer M, Steuber H, Zollner TM, Steinmeyer A, Schmidt N. Bothe U, et al. Among authors: wengner am. J Med Chem. 2024 Jan 25;67(2):1225-1242. doi: 10.1021/acs.jmedchem.3c01714. Epub 2024 Jan 16. J Med Chem. 2024. PMID: 38228402 Free PMC article.
Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models.
Pusch FF, Dorado García H, Xu R, Gürgen D, Bei Y, Brückner L, Röefzaad C, von Stebut J, Bardinet V, Chamorro Gonzalez R, Eggert A, Schulte JH, Hundsdörfer P, Seifert G, Haase K, Schäfer BW, Wachtel M, Kühl AA, Ortiz MV, Wengner AM, Scheer M, Henssen AG. Pusch FF, et al. Among authors: wengner am. Mol Cancer Ther. 2024 Apr 2;23(4):507-519. doi: 10.1158/1535-7163.MCT-23-0094. Mol Cancer Ther. 2024. PMID: 38159110 Free PMC article.
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
Sartori G, Tarantelli C, Spriano F, Gaudio E, Cascione L, Mascia M, Barreca M, Arribas AJ, Licenziato L, Golino G, Ferragamo A, Pileri S, Damia G, Zucca E, Stathis A, Politz O, Wengner AM, Bertoni F. Sartori G, et al. Among authors: wengner am. Br J Haematol. 2024 Jan;204(1):191-205. doi: 10.1111/bjh.19218. Epub 2023 Nov 27. Br J Haematol. 2024. PMID: 38011941
Targeted thorium-227 conjugates as treatment options in oncology.
Karlsson J, Schatz CA, Wengner AM, Hammer S, Scholz A, Cuthbertson A, Wagner V, Hennekes H, Jardine V, Hagemann UB. Karlsson J, et al. Among authors: wengner am. Front Med (Lausanne). 2023 Jan 9;9:1071086. doi: 10.3389/fmed.2022.1071086. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36726355 Free PMC article. Review.
Therapeutic targeting of ATR in alveolar rhabdomyosarcoma.
Dorado García H, Pusch F, Bei Y, von Stebut J, Ibáñez G, Guillan K, Imami K, Gürgen D, Rolff J, Helmsauer K, Meyer-Liesener S, Timme N, Bardinet V, Chamorro González R, MacArthur IC, Chen CY, Schulz J, Wengner AM, Furth C, Lala B, Eggert A, Seifert G, Hundsoerfer P, Kirchner M, Mertins P, Selbach M, Lissat A, Dubois F, Horst D, Schulte JH, Spuler S, You D, Dela Cruz F, Kung AL, Haase K, DiVirgilio M, Scheer M, Ortiz MV, Henssen AG. Dorado García H, et al. Among authors: wengner am. Nat Commun. 2022 Jul 25;13(1):4297. doi: 10.1038/s41467-022-32023-7. Nat Commun. 2022. PMID: 35879366 Free PMC article.
A Novel NAMPT Inhibitor-Based Antibody-Drug Conjugate Payload Class for Cancer Therapy.
Böhnke N, Berger M, Griebenow N, Rottmann A, Erkelenz M, Hammer S, Berndt S, Günther J, Wengner AM, Stelte-Ludwig B, Mahlert C, Greven S, Dietz L, Jörißen H, Barak N, Bömer U, Hillig RC, Eberspaecher U, Weiske J, Giese A, Mumberg D, Nising CF, Weinmann H, Sommer A. Böhnke N, et al. Among authors: wengner am. Bioconjug Chem. 2022 Jun 15;33(6):1210-1221. doi: 10.1021/acs.bioconjchem.2c00178. Epub 2022 Jun 3. Bioconjug Chem. 2022. PMID: 35658441 Free PMC article.
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.
Berger M, Wortmann L, Buchgraber P, Lücking U, Zitzmann-Kolbe S, Wengner AM, Bader B, Bömer U, Briem H, Eis K, Rehwinkel H, Bartels F, Moosmayer D, Eberspächer U, Lienau P, Hammer S, Schatz CA, Wang Q, Wang Q, Mumberg D, Nising CF, Siemeister G. Berger M, et al. Among authors: wengner am. J Med Chem. 2021 Sep 9;64(17):12723-12737. doi: 10.1021/acs.jmedchem.1c00762. Epub 2021 Aug 24. J Med Chem. 2021. PMID: 34428039 Free article.
IL3RA-Targeting Antibody-Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic Malignancies.
Kirchhoff D, Stelte-Ludwig B, Lerchen HG, Wengner AM, Ahsen OV, Buchmann P, Märsch S, Mahlert C, Greven S, Dietz L, Erkelenz M, Zierz R, Johanssen S, Mumberg D, Sommer A. Kirchhoff D, et al. Among authors: wengner am. Cancers (Basel). 2020 Nov 20;12(11):3464. doi: 10.3390/cancers12113464. Cancers (Basel). 2020. PMID: 33233768 Free PMC article.
27 results